CN101773572A - 含那格列奈的中西药组合物 - Google Patents
含那格列奈的中西药组合物 Download PDFInfo
- Publication number
- CN101773572A CN101773572A CN 201010131313 CN201010131313A CN101773572A CN 101773572 A CN101773572 A CN 101773572A CN 201010131313 CN201010131313 CN 201010131313 CN 201010131313 A CN201010131313 A CN 201010131313A CN 101773572 A CN101773572 A CN 101773572A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese
- diabetes
- nateglinide
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 26
- 239000000203 mixture Substances 0.000 title claims abstract description 18
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 title claims abstract description 13
- 229960000698 nateglinide Drugs 0.000 title claims abstract description 10
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 15
- 239000000284 extract Substances 0.000 claims abstract description 9
- 241000545442 Radix Species 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 235000016993 Agrimonia Nutrition 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 241001092084 Agrimonia Species 0.000 claims 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 229940079593 drug Drugs 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000002218 hypoglycaemic effect Effects 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 229940123208 Biguanide Drugs 0.000 description 3
- 239000003390 Chinese drug Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 229940127003 anti-diabetic drug Drugs 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 150000004283 biguanides Chemical class 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- WVAKABMNNSMCDK-UHFFFAOYSA-N sulfacarbamide Chemical compound NC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 WVAKABMNNSMCDK-UHFFFAOYSA-N 0.000 description 2
- 229950010053 sulfacarbamide Drugs 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 201000010000 Agranulocytosis Diseases 0.000 description 1
- 244000307697 Agrimonia eupatoria Species 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010018687 Granulocytopenia Diseases 0.000 description 1
- 206010020660 Hyperlactacidaemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000022329 Protein metabolism disease Diseases 0.000 description 1
- 244000179560 Prunella vulgaris Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000002079 cooperative effect Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003677 hemocyte Anatomy 0.000 description 1
- 229940000351 hemocyte Drugs 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 206010062198 microangiopathy Diseases 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明涉及一种含有那格列奈和中药提取物的协同药用组合物，以及该组合物在制备治疗糖尿病的药物中的应用。
Description
技术领域
本发明涉及一种治疗糖尿病的中西药组合物，具体地说是含有那格列奈和中药提取物的组合物，以及该组合物在制备治疗II型糖尿病药物中的用途。
背景技术
糖尿病是世界上严重危害人类健康的几大疾病之一，目前的治疗药品均不理想。例如，磺脲类药和双胍类药，疗效低，副作用大，久用可产生高乳酸血症，有的可造成致命性低血糖，磺脲类药久用损害肝脏、肾脏和血细胞。胰岛素久用产生抗体，增加剂量，易促使微血管疾病。目前虽然也有治疗糖尿病的中成药，但效果均不十分明显。糖尿病终身不愈，并发症广泛而严重，由于血液中胰岛素相对或绝对缺乏，引起糖、脂肪、蛋白质代谢紊乱，导致高血糖，高血脂及血液粘度的升高，中晚期出现周身广泛微血管病变。其中70％-80％患者死于心血管疾病，糖尿病肾功能衰竭；脑血管意外是中老年糖尿病患者常见死亡原因。
临床治疗II型的药物除胰岛素外，多是化学药物，应用广泛的大致可分为磺脲类、双胍类、其他降糖药及辅助用药。磺脲类降糖药物是最主要的糖尿病治疗药物。能使肝糖原合成增多，再通过对细胞受体或受体后的作用，使周围组织对胰岛素的敏感性增强，对葡萄糖的摄取增多，从而达到降低血糖的作用。但较易引发低血糖、粒细胞减少及心血管疾病等不良反应。双胍类降糖药大剂量可引起消化道反应，在肺、肝、肾有病变的患者易致乳酸性酸中毒。给广大患者用药安全带来隐患，为改变这种状况，长期以来，临床上一直尝试用植物中草约进行治疗。中医对糖尿病的病因看法较一致，认为主要是过食肥甘、五志过极、房室不节、热病火燥及先天禀赋不足几个因素。但中药亦存在一些不足，如起效慢、需在有经验老中医指导下辨正使用等。本发明尝试将中药与西药结合起来，以避免各自存在的问题，并提高对糖尿病的治疗效果，即产生协同作用。
发明内容
本发明的一个目的在于提供由那格列奈和一种中药提取物组成的药用组合物，其中该组合物的中药提取物按照以下配方制备，如下：以重量计将生地10份、首乌10份、白术5份、黄芪5份、元参8份、仙鹤草10份、桑叶8份，加水煎煮，过滤，浓缩至稠膏，干燥。
本发明的一个目的在于提供上述药用组合物在制备治疗糖尿病的药物中的用途。
该中药浸膏在下文中称作“本文(或上文)所述的中药提取物”。
可将上述组合物与药学上可接受的辅料混合制成临床上可接受的剂型，如片剂、胶囊、颗粒剂、口服液体制剂、皮下给药制剂、栓剂等。
药理作用研究
本发明药用组合物的主要药效学研究证实了其具有较强抗糖尿病作用，即降血糖作用。
参照张均田主编，《现代药理试验方法》(上册)，北京医学中国协和医科大学联合出版社，第984-985页，“第二节类似II型糖尿病的动物模型”中公开的方法，建立实验性肥胖及糖尿病大鼠模型，进行本发明的药用组合物降血糖的药效学试验。
试验分组：
1模型对照组：动物模型造模成功后，正常生理盐水灌胃；
2纯中药组：如上文所述的浸膏1.00g/kg体重灌胃
3那格列奈组：10mg/kg体重灌胃
4组合物组：10mg/kg体重那格列奈+上文所述的浸膏1.00g/kg体重灌胃。
该表显示治疗各组(纯中药组、那格列奈组、组合物组)均与模型对照组存在显著性差异，而组合物组与纯中药组、组合物组与那格列奈组均存在显著性差异。显示组合物组中的那格列奈与所述的中药组分存在协同效应。
药剂学试验
可按照常规方式生产含有下列组分的片剂：
本发明的药用组合物 200-700
玉米淀粉 100.0
滑石粉 70.0
硬脂酸镁 1.0
其中组合物由那格列奈和所述中药提取物以重量比1∶100组成。
可按照常规方式生产含有下列组分的胶囊：
本发明的药用组合物 200-700
乳糖 10.0
玉米淀粉 15.0
滑石粉 5.0
其中组合物由那格列奈和所述中药提取物以重量比1∶100组成。
Claims (2)
1.一种治疗糖尿病的组合物，其特征在于由那格列奈和中药提取物以重量比1∶100组成，其中该中药提取物按照下列方法制成：
以重量计将生地10份、首乌10份、白术5份、黄芪5份、元参8份、仙鹤草10份、桑叶8份，加水煎煮，过滤，浓缩至稠膏，干燥。
2.如权利要求1所述的组合物在制备治疗糖尿病的药物中的用途。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101313132A CN101773572B (zh) | 2010-03-24 | 2010-03-24 | 含那格列奈的中西药组合物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101313132A CN101773572B (zh) | 2010-03-24 | 2010-03-24 | 含那格列奈的中西药组合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101773572A true CN101773572A (zh) | 2010-07-14 |
| CN101773572B CN101773572B (zh) | 2012-05-23 |
Family
ID=42510247
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010101313132A Active CN101773572B (zh) | 2010-03-24 | 2010-03-24 | 含那格列奈的中西药组合物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101773572B (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102274514A (zh) * | 2011-07-20 | 2011-12-14 | 天津市聚星康华医药科技有限公司 | 一种用于预防和治疗2型糖尿病及并发症的药物组合物 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101199756A (zh) * | 2007-12-17 | 2008-06-18 | 孙丹凤 | 一种治疗糖尿病的药物 |
-
2010
- 2010-03-24 CN CN2010101313132A patent/CN101773572B/zh active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101199756A (zh) * | 2007-12-17 | 2008-06-18 | 孙丹凤 | 一种治疗糖尿病的药物 |
Non-Patent Citations (1)
| Title |
|---|
| 《中医药学刊》 20030831 陈大舜等 2型糖尿病及并发症23139例调研分析研究 第1225-1228,1273页 1-2 第21卷, 第8期 2 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102274514A (zh) * | 2011-07-20 | 2011-12-14 | 天津市聚星康华医药科技有限公司 | 一种用于预防和治疗2型糖尿病及并发症的药物组合物 |
| CN102274514B (zh) * | 2011-07-20 | 2014-08-27 | 天津市聚星康华医药科技有限公司 | 一种用于预防和治疗2型糖尿病及并发症的药物组合物 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101773572B (zh) | 2012-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102526479A (zh) | 一种增强免疫力、降血糖功能的保健药物配方 | |
| CN102526478A (zh) | 一种增强免疫力、降血糖功能的保健药物配方 | |
| CN102872334B (zh) | 一种药物组合物在防治糖尿病中的应用 | |
| CN101773624A (zh) | 一种用于治疗糖尿病的中药组合物及其制备方法 | |
| CN101264203B (zh) | 治疗糖尿病的中西药组合物 | |
| CN101773572B (zh) | 含那格列奈的中西药组合物 | |
| CN101757253B (zh) | 含格列喹酮的中西药组合物 | |
| CN102266391A (zh) | 可同时调节餐后和空腹血糖的药食同源植物提取的组合物 | |
| CN101791350B (zh) | 含格列本脲的中西药组合物 | |
| CN101791351B (zh) | 含格列吡嗪的中西药组合物 | |
| CN102018852A (zh) | 参连消渴降糖胶囊及制作工艺 | |
| CN104644734A (zh) | 一种治疗ⅱ型糖尿病及其并发症的药物 | |
| CN101791352B (zh) | 含苯乙双胍的中西药组合物 | |
| CN107213197A (zh) | 一种中药组合物及其在制备预防或治疗高血压药物中的应用 | |
| CN103566227B (zh) | 一种防治2型糖尿病的中药组合物及其制备方法 | |
| CN103181945B (zh) | 丝瓜子的用途 | |
| CN101406576B (zh) | 一种治疗糖尿病的中药及制备方法 | |
| CN100363000C (zh) | 含罗格列酮的中西药组合物及其制备方法 | |
| CN104983759A (zh) | 一种治疗糖尿病肾病的中药组合物及其制备方法 | |
| CN101406642A (zh) | 一种降糖的复方制剂 | |
| CN1327879C (zh) | 治疗糖尿病的药物及其制备方法 | |
| CN104027450B (zh) | 一种治疗糖尿病的中药组合物 | |
| CN100381150C (zh) | 含依帕司他的组合物 | |
| CN100362988C (zh) | 含二甲双胍的中西药组合物 | |
| CN100362998C (zh) | 治疗糖尿病的组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| DD01 | Delivery of document by public notice |
Addressee: Hu Keding Document name: Notification of Passing Preliminary Examination of the Application for Invention |
|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: RUDONG TECHNOLOGY CENTER Free format text: FORMER OWNER: HU KEDING Effective date: 20131202 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 315318 NINGBO, ZHEJIANG PROVINCE TO: 226400 NANTONG, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20131202 Address after: 226400, friendship road, Nantong Town, Rudong County, Jiangsu, 66 Patentee after: Rudong science and Technology Center Address before: 315318 Wu Meicun, Henghe Town, Cixi, Zhejiang Patentee before: Hu Keding |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200413 Address after: No. 10, Fandi South Road, juegang Town, Rudong County, Nantong City, Jiangsu Province Patentee after: Rudong industrial and commercial information consulting service center Address before: 226400, friendship road, Nantong Town, Rudong County, Jiangsu, 66 Patentee before: Rudong science and Technology Center |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20210826 Address after: 226400 No.8, wisdom Avenue, Donghu scenic area, Dayu Town, Rudong County, Nantong City, Jiangsu Province Patentee after: Nantong Donghu International Travel Agency Co., Ltd Address before: 226400 No.10 Fandi South Road, juegang Town, Rudong County, Nantong City, Jiangsu Province Patentee before: Rudong industrial and commercial information consulting service center |